Infusystems ($INFU) released Fourth Quarter 2015 and Full Year 2015 earnings today which were very good. The company has executed very well over the past 3 years and momentum is really building in terms of revenue growth and earnings growth. I wanted to cover some of my thoughts about the 2015 10-K, conference call, and news release. I’ve been invested in $INFU for a few years now, and I believe the business is still on the right track to keep growing and producing cash flow for the foreseeable future. Highlights for the full year 2015: Revenue of $72.1m...
2013 Year End Review
The year 2013 is now complete, and the stock market overall had a very good year and so did my investments. I wanted to write-up a few of the mistakes that I made throughout the year and include a top 5 post list. I’ve come to appreciate the publicizing of my mistakes because it requires that I review my decisions and to have a public record of the mistakes so that I do not make the same mistakes again. Mistakes made during 2013 Do not attempt to invest in areas that are outside of your knowledge – I attempted...
Infusystems ($INFU) and the Round 1 Recompete Analysis
I’ve noticed a few more SeekingAlpha articles (here and here) discussing the investment in $INFU, including discussions about the result of the CMS Round 1 Recompete. If you would like to read more about the Recompete process, you can visit the CMS website. In a nutshell, the Durable Medical Equipment suppliers for patients using Medicare and Medicaid were included in the new Recompete (competitive bidding) process. The goal of the bidding process is to finalize a price for services and equipment that for reimbursement by the government. Each item category includes items listed in a Healthcare Common Procedure Coding System (HCPCS). So, the...
InfuSystem Holdings ($INFU) 2013 Annual Meeting
I took a few days off from work around Labor day to go visit my mom in Vermont. I hadn’t been back to Vermont for several years, so I wanted to get back before it was too cold for my liking. During this time, $INFU had their annual meeting. I did not attend the meeting since I was flying to Vermont, but would have liked to have gone. I would love to hear from anyone that attended the meeting and would like to give me a summary. Management also released an 8-k with an investor presentation attached! It is...
InfuSystem Holdings Q2 2013 Review
$INFU released their 2013 Q2 earnings and completed their conference call. You can read the 10Q and conference call transcripts from the links. Since the recent failed take private situation, I wanted to review what is happening with the company. Positive Revenue up 4% from Q2 2012 Management has made strides in expanding their business model outside of the oncology market. Meaningful revenue was not shown this quarter, but it’s good to see that the company is expanding to other markets. Long-term care is one of markets, which is a good market to enter, along with post-surgical pain. These...
Ryan Morris makes his initial bid for INFU
Last night, Meson Capital Partners (i.e. Ryan Morris) filed the anticipated offer to purchase InfuSystems. The offer was for a price per share of between $1.85 to $2.00 in cash. I view this as an initial offer, as the price is at the low end of the range I was expecting. If you want to read the letter, click here and read the short letter. From the language in the letter, it sounds like a purchase can happen quickly if the special committee and Meson Capital can agree upon a satisfactory price. $INFU closed the day yesterday at $1.55...
Update on $INFU and Ryan Morris
Due to travel and my day job, I have not had a lot of time to keep up with the blog. Over the past weeks, I have been keeping track of my investments and potential ideas, but just haven’t had enough time to put something on the blog. It could also have to do with the stock market’s continual rise and not finding too many interesting ideas. I’ve written up InfuSystems ($INFU) awhile back and with the release of their latest quarterly earnings, some new developments have happened that create an interesting situation. First, the results for the first...
Update on $INFU based upon 2012 10-K
Infusystem ($INFU) released their 2012 10-K on March 28th. This is the first annual report released since the new management team took over in the spring of 2012. Lots of changes have occurred throughout the year, so I was anticipating the release of this report. You can read my initial writeup on INFU to get some background information. A quick summary of the situation is that the old management group did a very poor job at creating shareholder value for a business that generated high gross margins and growing revenues, ~10% per year. An activist shareholder group took control of the board,...